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Abstract  Breast  MRI  should  not  be  used  for  differential  diagnosis  between  inﬂammatory  breast
cancer and  acute  mastitis  (AM)  prior  to  treatment.  When  mastitis  symptoms  persist  after  10  to
15 days  of  well-managed  medical  treatment,  MRI  may  be  performed  in  addition  to  an  ultrasound
examination,  a  mammogram  and  to  taking  histological  samples,  in  order  to  eliminate  inﬂamma-
tory breast  cancer  (IBC).  For  staging,  MRI  would  seem  to  be  useful  in  looking  for  a  contralateral
lesion, PET-CT  for  ﬁnding  information  about  remote  metastases  and  in  certain  centres,  for  infor-
mation about  the  initial  extension  to  local/regional  lymph  nodes,  which  would  guide  the  ﬁelds
of irradiation  (since  patients  can  become  lymph  node  negative  after  neoadjuvant  chemother-
apy). MRI  and  PET-CT  seems  to  be  useful  for  early  detection  of  patients  responding  poorly  to
neoadjuvant  chemotherapy  so  that  the  latter  may  be  rapidly  modiﬁed.
© 2011  Éditions  françaises  de  radiologie.  Published  by  Elsevier  Masson  SAS.  All  rights  reserved.
The  term  mastitis  is  used  when  the  breast  is  inﬂamed,  for  whatever  reason,  resulting
in  a  breast  that  is  red,  hot  and  possibly  painful.  Two  recent  studies  report  the  aetiological
diagnoses  of  patients  consulting  for  breast  inﬂammation  in  specialised  breast  centres  [1,2].
According  to  these  studies,  the  number  of  consultations  for  breast  inﬂammation  is  low,
estimated  to  be  0.6%  of  consultations  (22/3762).  Infection  is  the  commonest  diagnosis  for
breast  inﬂammation  and  is  said  to  be  found  in  more  than  half  of  the  cases  (54  to  67%).  Non-
infectious  mastitis  is  also  common,  representing  about  a  third  of  the  consultations  with
many  different  aetiologies  including  post-therapeutic  sequelae,  systemic  diseases  (lupus,
sarcoidosis  etc.),  and  granulomatous  or  plasma  cell  mastitis.  Finally,  inﬂammatory  breast
cancer,  which  must  always  be  borne  in  mind,  is  the  least  common  differential  diagnosis,
representing  between  4.5  to  5.6%  of  consultations  for  breast  inﬂammation.
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nipple  abnormalities  (67%  versus  52%),  prominent  mam-Breast  inﬂammation:  Indications  for  MRI  and  PET-CT  
Given  the  frequency  of  acute  mastitis  (AM)  relative  to
inﬂammatory  breast  cancer  (IBC),  it  is  common  practice  to
give  a  case  of  acute  mastitis  a  trial  antibiotic  treatment
for  10  days  if  it  is  accompanied  by  fever,  and  otherwise
to  initiate  non-steroidal  anti-inﬂammatory  drugs  (NSAID)
treatment.  Complete  regression  of  the  symptoms  is  one  of
the  best  arguments  conﬁrming  the  diagnosis  of  AM.  If  the
symptoms  do  not  subside,  an  inﬂammatory  cancer  must  be
eliminated,  even  if  the  incidence  of  this  disease  is  low,  and
skin  and  breast  biopsies  must  be  performed  rapidly.  Inﬂam-
matory  breast  cancer  is  in  fact  a  therapeutic  emergency,
and  no  exploratory  examination,  in  particular  a  MRI,  should
delay  management  of  the  condition.
Imaging
Diagnosis and characterisation
Diagnosis  of  infectious  mastitis  is  clinical.  Favourable  evo-
lution  with  antibiotic  treatment  in  15  days  conﬁrms  this
diagnosis.  An  ultrasound  examination  can  be  useful  in  young
women  to  eliminate  an  abscess.
Figure 1. MRI appearance of an inﬁltrating ductal carcinoma (SBR gra
inﬂammation and an orange peel skin (PEV 3). The T2 sequence (a) sh
hypersignal possibly indicating parietal inﬁltration. The T1 (b) and subtr
of irregular shape with irregular margins, with early intense enhancem
sequence (c) also shows skin thickening (arrow head) and inﬁltration of 
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MRI  should  not  be  used  for  differential  diagnosis  between
nﬂammatory  breast  cancer  and  acute  mastitis  prior  to  any
rial  treatment  (evidence  level  1b,  recommendation  level
)  [3].  After  well-managed  medical  treatment  of  a  pre-
umed  mastitis,  a  breast  MRI  may  be  performed  if  there
re  still  doubts  about  the  presence  of  an  underlying  cancer
conventional  imaging)  (evidence  level  2b,  recommendation
evel  C)  [3].  This  examination  should  not  delay  breast  biop-
ies.  Nevertheless,  MRI  could  help  locate  a  target  hidden
n  ultrasound  and  mammography  examinations  by  oedema,
hich  increases  the  density  of  the  breast  parenchyma  (over-
ll  attenuation  with  ultrasound  and  type  III  or  IV  density  in
 mammogram).
However,  differentiating  between  cancer  and  acute  mas-
itis  remains  a  challenge  even  with  MRI.  Indeed,  these  two
onditions,  both,  exhibit  signs  of  inﬂammation  [4,5]: skin
hickening  (83%  versus  67%  for  IBC  and  AM  respectively),
n  increase  in  the  size  of  the  breasts  (69%  versus  62%),de III, triple negative) of the left breast, with clinically cutaneous
ows inﬂamed and thickened skin and a pectoralis major muscle
acted injected T1 sequences (c) show a homogeneous mass (star)
ent (d) followed by washout (type 3). The subtracted injected T1
the pectoralis major muscle (arrow).
ary  vessels  (85%  versus  71%),  cutaneous  oedema  in  T2
ypersignal  (81%  versus  67%),  and  oedema  of  the  breast
arenchyma  (90%  versus  83%).  Dynamic  criteria  do  not  seem
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Figure 2. MRI appearance of an inﬁltrating ductal carcinoma (SBR grade III, triple negative, with P53 mutation) of the right breast, clinically
PEV 3. The T2 sequence (a) shows a right pectoralis major muscle hypersignal (solid arrow head), which is asymmetric relative to the left
pectoralis major muscle (hollow arrow head). The T1 (b), injected T1 (c) and subtracted injected T1 (d) sequences show enhancement of
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lhe pectoralis major muscle which conﬁrms tumour inﬁltration. The
rregular margins (star).
o  be  really  discriminating  either.  Intense  early  enhance-
ent  (>  100%  before  90  s)  is  found  in  the  majority  of  cases
f  IBC  (80%—90%)  but  also  in  nearly  half  of  AM  patients
45%—55%).  On  the  other  hand,  kinetics  with  a  washout
Fig.  1)  seem  to  be  more  often  associated  with  IBC  (69%)
han  with  AM  (14%)  [4,5]. The  enhancement  kinetics  for  IBC
nd  AM  are  similar  because  both  the  tumoural  and  inﬂam-
atory  angiogenesis  phenomena  are  caused  by  VEGF.  This
ytokine  increases  the  formation  of  microvessels  (responsi-
le  for  the  initial  intense  enhancement)  and  modiﬁes  the
ermeability  of  capillary  walls  (explaining  the  washout  and
edema)  [6].
The  signs  more  often  observed  in  IBC  than  in  AM  on  MRI
re  the  existence  of  masses  of  more  than  10  mm  (75%  ver-
us  31%  respectively)  and  axillary  adenopathy  (67%  versus
8%,  Fig.  1)  [4].  The  shape  of  the  masses  in  the  MRI  does  not
eem  to  be  a  criterion  discriminating  between  the  two  con-
itions,  since  irregular  masses  are  found  in  30%  of  cases  of
BC  and  27%  of  AM  cases.  On  the  other  hand,  irregular  mar-
ins  or  spicules  seem  to  be  more  often  seen  in  IBC  than  in
M  (82%  versus  53%).  Heterogeneous  internal  enhancement
nd  the  ‘‘blooming  sign’’  (a  progressive  increase  in  the  size
P
i
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7quences also show the irregularly shaped homogeneous mass with
f  the  lesion  after  injection:  63%  versus  32%),  would  also
eem  to  give  weight  to  malignity  [7,8]. Masses  seem  to  be
ore  often  hypo-intense  in  T2  weighting  in  IBC  (78%)  than
n  AM  (18%),  because  of  desmoplastic  ﬁbrous  remodelling
9,10]  more  often  associated  with  abscesses  or  granulomas
4,5,11].  Non-mass  type  enhancement  is  found  in  both  con-
itions.  The  lesions  tend  to  be  superﬁcial  in  infectious  AM
ecause  of  the  progression  of  microorganisms  inwards  from
he  nipple,  while  IBC  lesions  tend  to  be  central  or  deep
4].  Early,  intense,  punctiform  enhancement  in  the  cuta-
eous  layer  speaks  in  favour  of  cancer  (56%  versus  7%).
hese  lesions  are  often  present  (70  to  80%)  where  there
re  tumoural  emboli  of  the  lymphatic  vessels  of  the  skin
12].  The  T2  hypersignal  indicating  prepectoral  oedema  or
edema  in  the  pectoral  muscle  tends  to  indicate  IBC  (Fig.  1)
4].  This  particular  appearance  seen  in  IBC  is  explained
y  the  possible  obstruction  by  tumoural  emboli  of  deep
ymphatic  vessels  linked  to  the  internal  thoracic  network.
ectoral  muscle  signal  abnormalities  tend  to  be  discriminat-
ng  (Fig.  2),  (interruption  of  the  fatty  interface:  54%  versus
7%;  pathological  enhancement  of  the  muscle:  33%  versus
%)  [13].
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Figure 3. Staging of an inﬁltrating ductal carcinoma (SBR grade III, triple negative, with P53 mutation) of the left breast, clinically PEV
3 (a). Locally, the PET-CT with 18FDG shows the tumour (star) of the left breast and skin inﬁltration (arrow head). Regional staging shows
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bbilateral axillary, left subclavicular and mediastinal adenopathies (
(hollow arrow) metastases.
In  a  retrospective  study,  M.D.  Anderson’s  team  com-
pared  the  performance  of  mammography,  ultrasonography,
MRI  and  PET-CT.  It  appears  that  MRI  was  the  most  pre-
cise  examination  for  detecting  a  cancer  in  an  inﬂamed
breast  [14]. In  this  work,  MRI  detected  all  the  inﬂamma-
tory  cancers  and  PET-CT  found  them  in  96%  of  patients.
MRI  was  decidedly  more  precise  than  PET-CT  for  deﬁning
the  multifocality  and  the  multicentricity  of  tumours.  FDG-
PET  is  not  therefore  recommended  for  characterising  breast
lesions,  whether  they  are  inﬂammatory  or  not.  It  is  a  stan-
dard  with  a  level  of  evidence  A  in  the  SOR  system  [15,16].
Indeed,  the  majority  of  studies  have  shown  its  limitations  for
diagnosing  small  tumours  (<  1  cm),  for  certain  histological
sub-types  (carcinoma  in  situ  and  lobular  carcinoma)  and  for
well-differentiated  and  low-grade  tumours  [17]. Moreover,
18-ﬂuorodeoxyglucose  (FDG)  is  not  a  speciﬁc  marker  for  can-
cerous  lesions,  and  inﬂammatory  mastitis  can  intensely  ﬁx
the  tracer;  far  more  exceptionally,  certain  benign  lesions,
such  as  cytosteatonecrosis,  and  certain  ﬁbroadenomas  may
weakly  ﬁx  FDG.  In  IBC,  PET-CT  shows  hypermetabolic,  often
multiple  (multifocal  and  multicentric)  foci  associated  with
thickened  skin,  which  is  also  hypermetabolic  (96%  sensi-
tivity).  Diffuse,  intense,  homogeneous  ﬁxation  or  ﬁxation
r
m
v) (b, c, d). The PET-CT also shows hepatic (black arrow) and bone
omposed  of  many  diffuse  foci  in  the  breast  associated  with
yperﬁxing-thickened  skin  is  also  possible  (Fig.  3)  [18,19].
taging
he  place  of  MRI  and  PET-CT  in  the  local/regional  staging
f  IBC  has  not  been  clearly  deﬁned.  The  potential  bene-
ts  expected  from  pre-operative  MRI  of  IBC  are  not  as  for
ther  types  of  cancer  (with  which  healthy  margins  can  be
btained  and  reduced  rates  of  local  recurrence),  as  almost
ll  the  patients  will  have  a  mastectomy.  The  objective  of
ocal/regional  staging  is  to  look  for  a  contralateral  cancer,
hich  is  more  frequent  in  IBC  (bilateral  involvement  being
ound  in  4  to  30%,  Fig.  4)  [20,21],  but  there  is  no  informa-
ion  in  the  literature  conﬁrming  or  refuting  the  usefulness  of
erforming  MRI  to  study  the  contralateral  breast  [3].  As  for
ther  types  of  breast  cancer,  histological  evidence  is  neces-
ary  of  supernumerary  lesions,  detected  in  the  contralateral
reast  by  MRI,  to  plan  the  best  surgery  (evidence  level  1b,
ecommendation  level  A)  [3].  MRI  and  any  histological  tests
ust  not  delay  treatment.
Patient  management  for  IBC  is  generally  by  neoadju-
ant  chemotherapy,  followed  by  a  mastectomy  with  axillary
108  C.  de  Bazelaire  et  al.
Figure 4. MRI appearance of an inﬁltrating ductal carcinoma (SBR grade II) of the right breast, clinically PEV 3. The MRI shows a cancer
of the right breast in the form of a regional homogeneous non-mass (star) and skin thickening. On the left, the MRI shows homogeneous,
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regmental enhancement without a mass (ACR 4). A microbiopsy of
SBR grade II).
ymph  node  dissection,  radiotherapy  and,  depending  on  the
ase,  adjuvant  chemotherapy.  Axial  lymph  node  dissection
erformed  as  a  second  course  of  action  can  prove  nega-
ive  due  to  the  efﬁcacy  of  the  initial  chemotherapy,  but
nowledge  of  an  initial  invasion  of  the  axilla  can  be  useful
nformation,  particularly  for  guiding  the  ﬁelds  for  radio-
herapy.  Ultrasound  is  the  best  examination  for  removing
uspicion  from  a  clinically  palpable  node  and  for  detecting
bnormal  non-palpable  lymph  nodes.  However,  PET-CT  also
ppears  to  perform  well  for  lymph  node  staging,  particu-
arly  in  detecting  invasion  beyond  levels  1  and  2  of  the  axilla
invasion  of  the  subclavicular,  supraclavicular  and/or  inter-
al  thoracic  chains)  (Fig.  3)  [22,23].  On  the  other  hand,  the
recision  of  PET-CT  or  MRI  of  the  breast  is  not  good  enough
o  replace  surgical  exploration  of  the  axilla  [24,25].
IBC  is  an  aggressive  cancer  with  a  strong  tendency
owards  early  metastasis  [26]. The  place  of  PET-CT  in
he  management  of  IBC  is  therefore  essentially  in  staging
emote  metastases  [22]. PET-CT  allows  metastatic  stag-
ng  with  excellent  diagnostic  precision  (sensitivity  100%,
peciﬁcity  93%,  positive  predictive  value  100%  and  negative
redictive  value  90%).  PET-CT  with  FDG  is  indeed  more  sensi-
ive  than  so-called  conventional  imaging  for  staging  remote
n
n
clesion of the left breast revealed an inﬁltrating ductal carcinoma
etastases,  particularly  in  the  mediastinal  lymph  nodes,
iver,  abdomen  and  bone  (Fig.  3)  [27]. Several  studies  have
eported  the  superiority  of  PET-CT  over  bone  scintigraphy
or  detecting  bone  metastases,  but  with  poorer  performance
or  blastic  lesions,  underlining  the  importance  of  simulta-
eously  reading  CT  images,  or  even  of  an  additional  bone
cintigraphy  examination.  The  other  PET-CT  false  negatives
re  essentially  small-size  lesions,  particularly  in  pulmonary
nd  hepatic  parenchyma.  As  far  as  false  positive  foci  are  con-
erned,  they  are  essentially  the  prerogative  of  infectious  or
nﬂammatory  phenomena.
herapeutic monitoring
he  therapeutic  sequence  for  IBC  consists  of  neoad-
uvant  chemotherapy  followed  by  treatment  combining
astectomy  and  local/regional  irradiation.  The  place  for
onservative  treatment  is  extremely  limited  considering  the
isk  of  recurrence  and  the  catastrophic  prognosis  accompa-
ying  it.
Many  studies  have  shown  that  MRI  is  a  better  tech-
ique  for  evaluating  the  effect  of  neoadjuvant  treatment
ompared  with  clinical  examination,  mammography  and
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Figure 5. MRI and PET-CT monitoring of a patient treated for inﬁltrating ductal carcinoma (SBR grade III, HER2 3+, RE negative, Rp
negative) of the right breast, clinically PEV 3, treated by neoadjuvant chemotherapy. Before treatment, the MRI morphological analysis
showed an oval, circumscribed mass (arrow), with annular enhancement and central necrosis (a: T2, b: T1, c: injected T1, and d: subtracted
injected T1). Still before treatment, the tumoural enhancement kinetics show early, intense contrast uptake (267% at 2 minutes) followed
by a washout (type 3) (e). The diffusion sequence (f) shows restriction of the diffusion with an ADC measured at 1.0 × 10−3 mm2/s. In PET-CT
with 18FDG (g), hypermetabolism is seen in the tumour with an SUV measured as 12.
110  C.  de  Bazelaire  et  al.
Figure 6. MRI and PET-CT monitoring after two courses of chemotherapy (same patient as Fig. 5). After two courses, the MRI morphological
analysis shows an approx. Fifty percent reduction in volume of the mass (arrow) (a). Functional analysis shows less pejorative, intense (288%
at 2 minutes) but progressive (type 1) tumoural enhancement kinetics (b, c, d, e). The diffusion sequence (f) shows an increase in the
diffusion with an ADC measured at 1.5 × 10−3 mm2/s. In PET-CT with 18FDG (g), a clear reduction in hypermetabolism is seen in the tumour
with an SUV measured as 3.9. These morphological and functional data after two courses predict a good ﬁnal response.
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ultrasound  examination,  even  if  over-  and  underestimates
of  the  residual  condition  may  be  produced,  particularly
for  non-mass  lesions  and  tumours  fragmented  after  the
neoadjuvant  chemotherapy.  The  prime  objective  of  breast
MRI  is  moreover  based  on  its  ability  to  show  the  real  extent
of  the  lesion  after  treatment,  in  order  to  guide  the  choice
of  lumpectomy  or  mastectomy.  As  mastectomy  is  generally
recommended  in  the  case  of  IBC,  the  usefulness  of  MRI  can
be  understood  to  be  limited  to  evaluating  the  efﬁcacy  of
neoadjuvant  chemotherapies  on  the  IBC.  As  for  PET-CT,  it
has  no  place  in  the  evaluation  of  the  residual  condition
at  the  end  of  neoadjuvant  chemotherapy:  PET  sensitivity
is  low  for  this  indication,  partly  because  of  the  limited
spatial  resolution  of  the  PET  detectors  and  partly  because  of
post-chemotherapy  ‘‘metabolic  stunning’’  phenomena  [28].
MRI  and  FDG-PET  could  nevertheless  play  a  major  role  in
assisting  in  early  identiﬁcation  of  non-responding  patients
right  from  the  ﬁrst  course  of  chemotherapy,  so  that  treat-
ment  could  be  modiﬁed  without  having  to  wait  for  the  results
of  conventional  evaluation  examinations  (Figs.  5  and  6)
[29,30].The  usefulness  of  new  functional  imaging  techniques,
such  as  spectroscopy  and  diffusion,  for  making  an  early
assessment  of  the  efﬁcacy  of  neoadjuvant  treatments,  has
also  been  evaluated  in  several  studies  (which  included
b
i
a
iubtraction (c).
atients  being  managed  for  a  locally  advanced  tumour  and
atients  with  IBC).  No  speciﬁc  results  are  available  for  IBC
o  date.  It  is  to  be  noted  that  an  early  decrease  in  choline
oncentration,  from  the  24th  hour  after  treatment,  is  an
ndicator  of  a  good  response  [31]. Several  studies  have  also
hown  that  the  restriction  of  diffusion  decreases  in  good
esponder  patients,  indicating  a reduction  in  intratumoural
ell  density  (Figs.  5  and  6)  [32—35]. Restriction  in  initial
iffusion  before  treatment  may  have  prognostic  value  [36].
n practice
hen  faced  with  breast  inﬂammation,  the  most  common
iagnosis  is  simple  infectious  mastitis.  Ultrasound  may  be
seful  to  eliminate  an  abscess.  Most  cases  of  infectious
astitis  regress  rapidly  after  beginning  anti-infective
reatment.  Non-infectious  mastitis  generally  has  a  clinically
uspect  appearance.  A  series  of  examinations  includ-
ng  mammography,  ultrasonography  and  biopsy  is  thus
ecommended  to  eliminate  a  cancer  or  an  infection  before
eginning  corticosteroid  treatment.  MRI  of  the  breast  is  not
ndicated  in  the  treatment  of  acute  or  subacute  mastitis
nd  should  not  be  used  for  differential  diagnosis  between
nﬂammatory  breast  cancer  and  acute  mastitis  prior  to
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Answers
1.  No:  symptoms  persist  despite  17  days  of  well-managed
treatment.  An  underlying  cancer  must  be  eliminated  by
asking  for  a  mammogram,  an  ultrasound  examination,12  
reatment  (level  of  evidence  1b,  recommendation  level  A)
3].
When  the  symptoms  of  presumed  mastitis  do  not  subside
fter  10  to  15  days  of  well-managed  medical  treatment,
nother  series  of  ultrasound  and  mammography  examina-
ions  plus  cutaneous,  mammary  and  lymph  node  biopsies
ust  be  envisaged,  to  eliminate  inﬂammatory  breast
ancer.  A  breast  MRI  can  also  be  performed  if  doubt  persists
oncerning  the  presence  of  an  underlying  cancer  (level  of
vidence  2b,  recommendation  level  C)  [3].  MRI  must  not
elay  histological  biopsies  or  initiating  treatment  in  the
ase  of  inﬂammatory  cancer.
MRI  may  play  a  role  in  local/regional  staging  in  inﬂam-
atory  cancer,  in  looking  for  contralateral  lesions.  PET-CT
ould  be  useful  in  local/regional  lymph  node  and  remote
etastatic  staging.  MRI  and  PET-CT  could  also  be  used  for
arly  detection  of  non-responding  patients  so  that  an  inef-
ective  neoadjuvant  chemotherapy  can  be  rapidly  modiﬁed.
his  indication  is,  however,  not  as  yet  recommended.
TAKE-HOME  MESSAGES
Diagnosis  and  characterisation
• After  well  managed  medical  treatment  of  suspected
mastitis,  a  breast  MRI  may  be  performed  if  there  are
still  doubts  regarding  the  presence  of  an  underlying
cancer.
• The  following  criteria  do  not  discriminate
between  IBC  and  AM:  the  morphology  of
masses  and  non-masses,  increase  in  breast
size,  diffuse  skin  thickening,  abnormal  nipple
conﬁguration,  hypervascularisation,  and  cutaneous
or  subcutaneous  oedema.
• The  following  criteria  are  seen  more  frequently  in
IBC:  a  T2  hyposignal  mass  of  more  than  10  mm,  type
III  enhancement,  a  ‘‘blooming  sign’’,  inﬁltration  of
the  pectoralis  major  muscle,  oedema  (peri-focal,
prepectoral  and  intramuscular).  The  main  location
of  AM  is  generally  subareolar,  that  of  IBC,  central
and  posterior.
• PET-CT  is  not  indicated  for  characterisation.
Staging
• Breast  MRI:  would  be  useful  when  searching  for  a
contralateral  lesion.
• PET-CT:  would  be  useful  for  local/regional  lymph
node  staging  before  neoadjuvant  chemotherapy,  for
guidance  regarding  the  ﬁelds  to  be  irradiated  after
mastectomy.
• PET-CT:  performs  well  for  remote  staging.
Monitoring  neoadjuvant  chemotherapies
• MRI  and  PET-CT  seem  to  perform  well  for  early
evaluation  of  responders  and  non-responders,  which
can  allow  an  ineffective  treatment  to  be  changed.
• MRI  performs  well  for  evaluating  residual  tumour
volume  at  the  end  of  treatment,  to  guide
surgery.  Nevertheless,  the  expected  beneﬁt  of  this
monitoring  is  relative,  since  all  patients  have  a
mastectomy.C.  de  Bazelaire  et  al.
linical case
uestion 1
 50-year-old  patient  has  made  an  emergency  consultation
or  pain  in  the  right  breast,  which  has  evolved  over  the
ast  8  months;  the  breast  has  been  inﬂamed  for  5  days
ith  fever.  The  mammogram,  taken  8  months  ago  (not
vailable),  showed  cysts.  On  clinical  examination,  the
ollowing  is  noted:  tachycardia,  a sub-febrile  state,  no  signs
f  shock,  eupnoea,  clear  symmetrical  auscultation,  supple,
ainless  abdomen.
The  right  breast  is  inﬂamed  with  peri-nipple  plaque,  a
ubjacent  mass,  nipple  invagination.  No  axillary  adenopathy.
hat  imaging  examination(s)  would  you  ask  for?
.  None;
.  Ultrasonography;
.  Mammography;
.  MRI.
nswers
. Yes:  the  recommendation  is  to  start  antibiotic  and  anti-
inﬂammatory  treatment  and  reassess  the  situation  after
2  weeks;
. Yes:  it  is  reasonable  to  ask  for  an  ultrasound  examination
to  eliminate  an  abscess;
. Yes:  since  the  patient  is  more  than  35  years  old,  it  is
reasonable  to  ask  for  a  mammogram;
.  No:  MRI  should  not  be  used  for  differential  diagnosis
between  acute  mastitis  and  inﬂammatory  breast  cancer
before  a  trial  treatment  lasting  10  to  15  days.
uestion 2
he  patient  returns  to  the  breast  clinic  17  days  later.
he  volume  of  the  right  breast  has  increased  and  there
s  cutaneous  erythema,  particularly  affecting  the  central
egion  with  slight  nipple  retraction.  Palpation  is  painful.  No
erceptible  mass;  no  nipple  discharge  caused.  Examination
f  the  contralateral  breast  is  normal.  Homolateral  and
ontralateral  axillary  and  supraclavicular  lymph  nodes  are
ree.  What  imaging  examination(s)  would  you  ask  for?
.  None;
. Ultrasound  and  mammogram;
. Biopsies;
. MRI.and  skin  and  mammary  biopsies.  An  MRI  could  also  be
requested  to  look  for  a  tumour  which  might  be  poorly
visible  by  mammography  and  ultrasonography  because
of  oedema;
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Figure 8. Ultrasound: retroareolar region of the right breast (a), right breast mammogram: enlargement is focused on the external side
compartments (b); right breast mammogram: enlargement is focused on the upper compartments in oblique (c) PET-CT performed in the
staging (d).
A
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(2.  Yes;
3.  Yes;
4.  Yes.
Question 3
MRI  is  performed  (Fig.  7)  and  shows  enhancement  without
a  ductal  mass  in  the  superior  medial  quadrant  of  the
right  breast.  Ultrasound  examination  (Fig.  8a)  shows  duct
ectasias,  and  the  mammogram  (Fig.  8b:  CC,  and  8c:  MLO)
shows  a  few  diffuse  heterogeneous  large  micro-calciﬁcations
(ACR  3)  in  the  superior  medial  quadrant  of  the  right  breast.
A  stereotactically  guided  macrobiopsy  of  the  micro-
calciﬁcations  of  the  right  breast  is  performed  and  shows
dystrophy  without  atypia.  A  PET-CT  is  performed  for  staging
and  shows  no  hypermetabolic  foci  (Fig.  8d).  What  would
you  do?
1. A biopsy  under  MRI;
2.  A  new  stereotactically  guided  macrobiopsy;
3.  Mammographic,  ultrasonographic  and  MRI  monitoring;
4.  Nothing,  because  the  PET-CT  is  negative.
t
m
o
wnswers
.  Yes:  the  stereotactic  macrobiopsy  does  not  formally
eliminate  a  cancer;
. No:  sampling  was  performed  under  good  conditions
but  this  (the  micro-calciﬁcations)  was  not  the  right
target;
.  No:  there  is  an  ACR  4a-type  lesion  in  an  inﬂamed  breast:
cancer  must  be  rapidly  eliminated;
.  No:  PET-CT  is  not  sufﬁciently  sensitive  in  the  breast  to
formally  eliminate  a  small  cancer.
The  patient  refuses  another  macrobiopsy  and  is
onitored  by  MRI  after  4  months  (Fig.  9a)  and  8  months
Fig.  9b).  Compared  with  the  initial  MRI  (Fig.  9c  and  d),
hese  two  examinations  show  that  the  non-mass  enhance-
ent  has  disappeared  from  the  superior  medial  quadrant
f  the  right  breast.  A  year  later,  the  patient  is  doing
ell.
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